Stabilized Mcl-1 Binding Peptides for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to selectively target Mcl-1, a key anti-apoptotic protein in cancer cells, leading to resistance against chemotherapeutic agents, as existing agents often bind non-specifically to other Bcl-2 family proteins.
Innovation Solution
Development of structurally stabilized peptides that selectively bind human Mcl-1 with enhanced affinity by incorporating internally cross-linked amino acids, such as those with hydrocarbon staples, to disrupt Mcl-1's anti-apoptotic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing chemotherapeutic agents are used, then they can treat cancer, but they bind non-specifically to other Bcl-2 family proteins leading to resistance
Solution Approach 1:
The peptide is designed with specific local modifications including internal cross-links and non-natural amino acids at particular positions (e.g., positions 5 and 10) to enhance binding affinity and selectivity for Mcl-1 while maintaining the overall BH3 domain structure. This localized optimization allows the peptide to distinguish Mcl-1 from other Bcl-2 family proteins.
Solution Approach 2:
The peptide incorporates a composite structure combining natural amino acids with non-natural amino acids (e.g., Aib, Nle) and internal cross-links (e.g., disulfide bonds, hydrocarbon staples). This composite design enhances structural stability, resistance to proteolysis, and binding potency while maintaining selectivity for Mcl-1.
2Reliability
If peptides are designed to bind Mcl-1 with high affinity, then they can induce apoptosis, but they may lose structural stability
Solution Approach 1:
Internal cross-links are introduced at predetermined positions (e.g., between cysteine residues at positions 3 and 8) to pre-stabilize the peptide's alpha-helical structure before binding to Mcl-1. This preliminary structural reinforcement ensures the peptide maintains its binding-competent conformation and resists proteolytic degradation.
Solution Approach 2:
The peptide incorporates non-natural amino acids with specific properties (e.g., Aib for helical stabilization, Nle for protease resistance) and modifies structural parameters such as cross-linking density and amino acid composition to optimize both binding affinity and structural stability simultaneously.
3Reliability
If peptides are made more selective for Mcl-1, then they overcome chemotherapy resistance, but their interaction with other Bcl-2 proteins increases
Solution Approach 1:
Specific residues at key positions (e.g., hydrophobic residues at positions 4, 7, and 10) are optimized to match Mcl-1's binding groove characteristics while differing from other Bcl-2 family proteins. This local optimization enhances specificity without requiring complete exclusivity from all other proteins.
Solution Approach 2:
The peptide's charge distribution, hydrophobicity pattern, and structural rigidity are tuned through amino acid substitutions and cross-linking to achieve optimal selectivity for Mcl-1. The design accepts some degree of off-target binding as long as the primary therapeutic effect on Mcl-1-driven apoptosis is achieved.
Data Source
AI summary
Provided herein are stabilized peptides that bind Mcl-1. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.